Skip to main content

Table 4 Predictors of progression free survival

From: Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

Characteristic Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (per year) 0.997 0.962-1.033 0.861    
Gender (male vs. female) 0.892 0.268-2.969 0.852    
Liver cirrhosis (with vs. without) 0.939 0.401-2.202 0.886    
Child-Pugh class (A vs. B) 0.304 0.111-0.829 0.020 0.461 0.155-1.366 0.162
Main portal trunk invasion (with vs. without) 1.098 0.520-2.318 0.805    
Node metastasis (with vs. without) 0.809 0.393-1.664 0.565    
Baseline tumor size (per 1 cm) 1.045 0.958-1.140 0.317    
Baseline AFP (per 100 ng/mL) 1.000 0.997-1.002 0.827    
Baseline DCP (per 100 mAU/mL) 1.002 1.001-1.003 0.005    
Radiation dose (per 100 cGy) 0.931 0.866-1.001 0.054    
Objective response after CCRT (with vs. without) 0.560 0.267-1.174 0.125    
AFP after CCRT (per 100 ng/mL) 1.000 0.998-1.002 0.962    
DCP after CCRT (per 100 mAU/mL) 1.004 1.002-1.006 <0.001 1.003 1.001-1.005 0.001
Additional TACE (with vs. without) 0.590 0.269-1.299 0.190    
Round of HAIC 0.914 0.831-1.005 0.062    
  1. AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, CCRT Concurrent chemoradiation therapy, TACE Transarterial chemoembolization, HAIC Hepatic arterial infusional chemotherapy